截至本公告披露日，肖毅先生直接持有公司股票274,420股，占公司总股本 0.0761%，通过公司《2022年员工持股计划》间接持有20,000股，占公司总股本 的0.0055%。肖毅先生承诺，其直接持有的公司股份将严格遵守《上市公司股东 减持股份管理暂行办法》及《深圳证券交易所上市公司自律监管指引第18号—股 东及董事、监事、高级管理人员减持股份》等相关规定；通过公司《2022年员工 持股计划》间接持有的公司股份，也将遵守公司《2022年员工持股计划》及《2022 年员工持股计划管理办法》等有关规定进行相应处理。 肖毅先生在公司任职期间勤勉尽责、恪尽职守，搭建及整合了公司工艺科学 中心（CEPS）先进技术平台，积极推动高通量筛选平台建设和应用，推进光化学、 电化学等先进技术应用，助力公司CDMO业务开展的同时，进一步夯实了公司的技 术储备。在此，公司及董事会对肖毅先生为公司发展所作的贡献表示衷心的感谢！ 特此公告。 凯莱英医药集团（天津）股份有限公司董事会 证券代码：002821 证券简称：凯莱英 公告编号：2025-008 凯莱英医药集团（天津）股份有限公司 关于高级管理人员退休离任的公告 本公司及董事会 ...

呈交日期: 2025年3月3日 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 凱萊英醫藥集團（天津）股份有限公司 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06821 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 27,553,260 | RMB | | | 1 RMB | | 27,553,260 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 27,553,260 | RMB | | | 1 RMB | | 27,553,260 | | 2. 股份分類 ...

证券代码：002821 证券简称：凯莱英 公告编号：2025-007 凯莱英医药集团（天津）股份有限公司 关于回购股份注销完成暨股份变动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重要提示： 1、凯莱英医药集团（天津）股份有限公司（以下简称"公司"或"凯莱英"） 本次注销存放于回购专用证券账户中的部分股份 7,122,703 股，注销金额约 5.79 亿元，占注销前 A 股股本（340,164,843 股）的 2.09%，占注销前总股本的 1.94%。 本次回购股份注销完成后，公司 A 股股本由 340,164,843 股变更为 333,042,140 股，总股本 367,718,103 股由变更为 360,595,400 股。 2、经中国证券登记结算有限责任公司深圳分公司审核确认，公司本次回购 股份注销事宜于 2025 年 2 月 26 日办理完成。 一、公司股票回购及使用情况 公司于 2024 年 2 月 29 日召开 2024 年第二次临时股东大会、2024 年第二次 A 股类别股东大会及 2024 年第二次 H 股类别股东大会，审议通过了《 ...

Core Viewpoint - The company has approved a share repurchase plan, aiming to enhance shareholder value and investor confidence while maintaining operational stability and compliance with regulations [1][6]. Group 1: Share Repurchase Plan - The company will repurchase A-shares through centralized bidding in the secondary market, with a total fund amount not less than RMB 600 million and not exceeding RMB 1.2 billion, at a maximum price of RMB 157 per share [1]. - The repurchase price cap was adjusted to RMB 155.27 per share effective from June 28, 2024, due to dividend distributions and other corporate actions [2]. - As of the announcement date, the company has completed the repurchase of 12,300,701 shares, accounting for 3.6161% of the total A-share capital, with a total expenditure of approximately RMB 999.64 million [4]. Group 2: Implementation Details - The repurchase was conducted from March 7, 2024, to February 18, 2025, with the highest transaction price at RMB 102.00 and the lowest at RMB 71.65 per share [4]. - The company has adhered to the relevant regulations during the repurchase process, ensuring compliance with the Shenzhen Stock Exchange's guidelines [9][10]. Group 3: Impact and Future Plans - The share repurchase is expected to establish a long-term incentive mechanism, protect shareholder rights, and enhance investor confidence without significantly impacting the company's operations or financial health [6]. - The repurchased shares will be stored in a dedicated account and will not have voting rights or profit distribution rights during the holding period, with plans for future use in equity incentives or capital reduction [11].

证券代码：002821 证券简称：凯莱英 公告编号：2025-006 凯莱英医药集团（天津）股份有限公司 关于股份回购完成暨股份变动的公告 本公司及全体董事会成员保证公告内容真实、准确和完整，不存 在虚假记载、误导性陈述或重大遗漏。 凯莱英医药集团（天津）股份有限公司（以下简称"公司"）于 2024 年 2 月 29 日召开 2024 年第二次临时股东大会、2024 年第二次 A 股类别股东大会及 2024年第二次H股类别股东大会，审议通过了《关于回购公司股份方案的议案》。 根据股份回购方案，公司将采用集中竞价交易的方式从二级市场回购公司 A 股 股份，本次回购股份的资金总额将不低于人民币 60,000 万元（含），且不超过人 民币 120,000 万元（含）；回购价格不超过 157 元/股。具体内容详见刊登在《证 券时报》、《中国证券报》和巨潮资讯网（http://www.cninfo.com.cn）上的相关公告。 2024 年 6 月 6 日公司召开 2023 年度股东大会，审议通过了 2023 年年度权 益分派方案；本次权益分派股权登记日为 2024 年 6 月 27 日，除权除息日为 2024 年 6 ...

Investment Rating - The investment rating for the company is "Buy" [8]. Core Insights - The company is a leading player in the CDMO sector, providing comprehensive services for small molecule drugs and actively expanding into emerging business areas [1][19]. - The global biopharmaceutical industry is experiencing an upward demand trend, with a gradual improvement in the supply-demand structure for CDMO services [2][36]. - The small molecule business is stabilizing and entering a phase of commercial project harvest, while emerging businesses are also showing strong demand [3][4]. Summary by Sections 1. Company Overview - The company has established itself as a top-tier CDMO service provider, serving over 1,100 clients globally and forming strong collaborative ties with major pharmaceutical companies [1][19]. - It has a well-rounded service offering that includes small molecule drug lifecycle outsourcing, with a focus on high-grade and large-scale products [20]. 2. Industry Dynamics - The biopharmaceutical industry is on an upward trajectory, with a balanced supply-demand structure expected to develop by 2025 [2][36]. - Small molecules continue to dominate the market, accounting for approximately 54.86% of the industry in 2023, while new therapies like peptides and oligonucleotides are gaining traction [2][51]. 3. Business Performance - The small molecule business is expected to see stable growth, with 28 projects anticipated to reach the PPQ stage in 2024 [3]. - Emerging business segments, including peptides and oligonucleotides, are experiencing robust demand, with significant growth expected starting in 2025 [4]. 4. Financial Projections - Revenue projections for 2024-2026 are estimated at 5.886 billion, 6.761 billion, and 7.807 billion yuan, respectively, with corresponding net profits of 917 million, 1.163 billion, and 1.281 billion yuan [8][10]. - The company anticipates a recovery in revenue growth post-2024, driven by a rebound in demand and successful project commercialization [3][4].

证券代码：002821 证券简称：凯莱英 公告编号：2025-005 凯莱英医药集团（天津）股份有限公司 关于回购公司股份进展的公告 2024 年 6 月 6 日公司召开 2023 年度股东大会，审议通过了 2023 年年度权 益分派方案；本次权益分派股权登记日为 2024 年 6 月 27 日，除权除息日为 2024 年 6 月 28 日。公司在回购股份期内实施了派息、送股、资本公积金转增股本、 股票拆细、缩股、配股及其他除权除息事项，自股价除权除息之日起，按照中国 证监会及深圳证券交易所的相关规定相应调整回购股份价格并及时披露。调整后 的回购价格上限为 155.27 元/股，自 2024 年 6 月 28 日（除权除息日）起生效。 具 体 内 容 详 见 刊 登 在 《 证 券 时 报 》、《 中 国 证 券 报 》 和 巨 潮 资 讯 网 （http://www.cninfo.com.cn）上的相关公告。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回购股份（2023 年修订）》等相关规定，公司在回购期间，应当在每个 月的前 3 个交易日内公告截至上月末的回购进展情况； ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 凱萊英醫藥集團（天津）股份有限公司 第 1 頁 共 11 頁 v 1.1.1 備註： FF301 由於凱萊英醫藥集團（天津）股份有限公司於中華人民共和國註冊成立，因此「法定股本」的概念並不適用。第一部分所載資料所指的是「已發行股本」。 第 2 頁 共 11 頁 v 1.1.1 呈交日期: 2025年2月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06821 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 27,553,260 | RMB | | | 1 RMB | | 27,5 ...

Investment Rating - The investment rating for the company is "Buy" [6] Core Views - The company is expected to achieve a net profit attributable to shareholders of 850 million to 1.05 billion yuan in 2024, representing a year-on-year decline of 54% to 63%. However, a quarter-on-quarter growth of approximately 35% is anticipated in the fourth quarter [1] - The company's revenue for 2024 is projected to be between 5.8 billion and 6 billion yuan, reflecting a year-on-year decrease of 23% to 25%, with a quarter-on-quarter growth of about 20% in the fourth quarter [1] - The company has launched a stock incentive plan, indicating confidence in long-term development, with a total of 521.6 million shares for A-shares and 148.5 million shares for H-shares [2][3] Summary by Sections Financial Performance - In 2024, the company expects a net profit of 1 billion yuan, with a year-on-year decline of 55.8% in 2024, followed by growth rates of 22.1% in 2025 and 29.3% in 2026 [4] - Revenue is projected to decline by 24.6% in 2024, but is expected to grow by 17% in 2025 and 17.2% in 2026 [5] Business Segments - The small molecule CDMO business is expected to grow by approximately 11% year-on-year, while emerging businesses are projected to grow by about 3% [2] - The large molecule business has shown positive trends, with fourth-quarter revenue accounting for over 45% of the annual total [2] Incentive Plans - The A-share incentive plan targets 649 individuals, including directors and key personnel, with a stock grant of 521.6 million shares, representing 1.53% of the total A-share capital [3] - The incentive plan aims for revenue growth targets of 10-13% in 2025, 20-27% in 2026, and up to 53% in 2028 based on 2024 revenue [3] Market Outlook - The company is focusing on accelerating overseas capacity expansion, rebalancing profitability, and enhancing new business development [4] - The overall order intake has increased by approximately 20% year-on-year, with strong growth from clients in Europe and the US [2]

Financial Performance - The company expects net profit attributable to shareholders to be between CNY 850 million and CNY 1.05 billion, a decrease of 54%-63% compared to the previous year[3]. - The projected operating revenue for 2024 is between CNY 5.8 billion and CNY 6 billion, representing a decline of 23%-25% year-on-year[5]. - The basic earnings per share are estimated to be between CNY 2.50 and CNY 3.00, down from CNY 6.26 in the same period last year[3]. Revenue Growth and Orders - The company achieved a year-on-year revenue growth of approximately 20% in Q4 2024, despite an overall decline in annual revenue[5]. - New orders signed throughout the year increased by approximately 20%, with growth in orders from European and American markets exceeding the overall order growth rate[6]. - The small molecule CDMO business showed a year-on-year growth of about 11% after excluding the impact of large orders from the previous year[5]. Emerging Business and Capacity Utilization - The emerging business revenue declined, and some segments are still ramping up, leading to lower capacity utilization and reduced gross margins[6]. - The company continues to invest heavily in new technology research and development, resulting in increased R&D expenses[6]. Business Trends and Developments - The chemical macromolecule business is showing positive trends in areas such as peptides, nucleic acids, and ADCs, with Q4 revenue accounting for over 45% of total annual revenue[6]. - The company’s UK Sandwich site began operations in the second half of the year and is currently in the ramp-up phase[6].